(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number
WO 2004/076458 A1

(51) International Patent Classification[7]: C07D 487/04, A61K 31/519, A61P 19/08, 35/00, 37/02, 43/00, 3/10, 13/12, 17/00, 27/00, 19/02, 7/00, 1/16, 21/04, 1/00, 17/06, 7/00, 1/16, 21/04, 1/00, 17/06

(21) International Application Number:
PCT/JP2004/002522

(22) International Filing Date: 1 March 2004 (01.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0304665.3	28 February 2003 (28.02.2003)	GB
60/500,695	8 September 2003 (08.09.2003)	US
0329446.9	19 December 2003 (19.12.2003)	GB


(71) Applicant *(for all designated States except US)*: **TEIJIN PHARMA LIMITED** [JP/JP]; 1-1, Uchisaiwaicho 2-chome Chiyoda-ku Tokyo, 1000011 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KATAOKA, Kenichiro** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **SUZUKI, Naotaka** [JP/JP]; c/o Teijin Pharma Limited 1-1, Uchisaiwaicho 2-chome Chiyoda-ku Tokyo, 1000011 (JP). **KOSUGI, Tomomi** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **IMAI, Minoru** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **MAKINO, Hiroaki** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **TAKAKUWA, Mika** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **UNOKI, Gen** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **FUJINO, Aiko** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **OUE, Yasuhiro** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **YAMAKOSHI, Yuko** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **SUGIURA, Satoshi** [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **MITCHELL, Dale Robert** [GB/GB]; c/o Bio Focus Chesterford Park Saffron Walden Essex, CB101XL

[Continued on next page]

(54) Title: PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES



(57) Abstract: The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. H,N,R^3

WO 2004/076458 A1

(GB). **SIMPSON, Donald James** [GB/GB]; c/o Bio Focus Chesterford Park Saffron Walden Essex, CB101XL (GB). **HARRIS, Clifford John** [GB/GB]; c/o Bio Focus Chesterford Park Saffron Walden Essex, CB101XL (GB). **LE, Joelle** [GB/GB]; c/o Bio Focus Chesterford Park Saffron Walden Essex, CB101XL (GB).

(74) **Agent: MIHARA, Hideko**; c/o Teijin Intellectual Property Center Limited 1-1, Uchisaiwaicho 2-chome Chiyoda-ku Tokyo, 1000011 (JP).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ABSTRACT

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.



(I)